Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases... Show more
VERU is expected to report earnings to rise 138.46% to -31 cents per share on August 06
Q2'26
Est.
$-0.31
Q1'26
Missed
by $0.07
Q4'25
Missed
by $0.20
Q3'25
Beat
by $0.15
Q2'25
Missed
by $0.45
The last earnings report on May 13 showed earnings per share of -12 cents, missing the estimate of -5 cents. With 198.19K shares outstanding, the current market capitalization sits at 47.83M.